针对德国风险人口认知衰退的多领域干预:来自集群随机化AgeWell.de试验的结果
Andrea E Zülke1, Alexander Pabst1, Melanie Luppa1
1Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 28, 2023
概括
这项研究发现,多领域干预并不能在患痴呆症风险较高的老年人中保持认知功能. 然而,它确实改善了生活质量,并减少了女性的抑郁症状.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 痴呆的风险随着年龄和心血管因素的增加而增加.
- 早期干预对于老年人群的认知健康至关重要.
- 多领域干预旨在通过改变生活方式来减轻痴呆风险.
研究的目的:
- 评估多领域干预措施在危险老年人中保持认知功能的有效性.
- 评估生活方式优化对认知衰退的影响.
- 为了确定COVID-19期间干预的坚持是否影响了结果.
主要方法:
- 集群随机试验涉及1030名参与者,年龄在60-77岁之间,心血管风险因素,衰老和痴呆症 (CAIDE) 评分高.
- 干预组接受了优化的营养,药物,身体,社会和认知活动.
- 对照组接受了24个月的一般健康咨询和常规护理.
主要成果:
- 干预组和对照组之间在总体认知表现上没有显著差异.
- 819名参与者完成了24个月的随访.
- COVID-19大流行并没有影响干预的有效性.
结论:
- 多领域干预没有证明在保护全球认知功能的有效性.
- 干预对所有参与者的健康相关生活质量产生了积极影响.
- 干预组内女性的抑郁症状有所减少.
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Cognitive Development During Adulthood
142
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
142
Community Based Intervention
57
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
57
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147


